Supriya Lifescience Ltd Stock Price Today (NSE: SUPRIYA)
Fundamental Score
Supriya Lifescience Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Supriya Lifescience Ltd share price today is ₹561.90, down 1.58% on NSE/BSE as of 30 March 2026. Supriya Lifescience Ltd (SUPRIYA) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹6.00K (Cr). The 52-week high for SUPRIYA share price is ₹842.00 and the 52-week low is ₹545.50. At a P/E ratio of 32.91x, SUPRIYA is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 20.75% and a debt-to-equity ratio of 0.00.
Supriya Lifescience Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Supriya Lifescience Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Supriya Lifescience Share Price: A Conservative Value Investor's Perspective
The pharmaceutical sector, particularly the Active Pharmaceutical Ingredients (API) segment, is currently navigating a period of margin compression due to raw material price volatility and increased competition. This analysis provides a conservative, value-oriented perspective on the Supriya Lifescience share price, currently trading at ₹669.25. We will focus on capital safety and long-term value creation, employing a fundamental audit approach verified by Sweta Mishra, encompassing over 80 parameters to assess the company's financial health and intrinsic worth.
The company's Price-to-Earnings (PE) ratio of 32.91 warrants careful consideration. Compared to some of its peers, this valuation appears rich. For instance, when looking at
Mankind Pharma Ltd, anecdotal evidence suggests a market perception of higher management quality, often reflected in a premium valuation. This premium isn't solely based on financials, but also on perceived competence and strategic foresight, aspects that are crucial for navigating the complexities of the pharmaceutical landscape.However, Supriya Lifescience's Return on Capital Employed (ROCE) of 27.46% is noteworthy. This robust ROCE indicates efficient capital allocation and strong profitability. A consistently high ROCE contributes to building a company's economic moat. It suggests that the company possesses a competitive advantage, potentially stemming from specialized product offerings, cost efficiencies, or strong customer relationships. This ability to generate superior returns allows the company to reinvest in its business, further strengthening its competitive position and fostering sustainable growth. We would also be looking at the debt to equity ratio to understand how they have funded their capital investments.
Ultimately, a conservative assessment of Supriya Lifescience requires a thorough understanding of its competitive advantages, management quality, and ability to sustain its profitability in a dynamic market. While the high ROCE is attractive, a detailed analysis, beyond the scope of this brief commentary, is needed to determine if the current Supriya Lifescience share price adequately reflects the inherent risks and opportunities.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Supriya Lifescience Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SUPRIYA across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (20.75%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (27.46%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (35.97%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (20.31%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (17.45% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (20.71% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (131.31x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (68.30%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Weak Earnings Growth (-14.16% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-56.28 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Supriya Lifescience Ltd Financial Statements
Comprehensive financial data for Supriya Lifescience Ltd including income statement, balance sheet and cash flow
About SUPRIYA (Supriya Lifescience Ltd)
Supriya Lifescience Ltd is a dynamic pharmaceutical company focused on developing, manufacturing, and distributing high-quality active pharmaceutical ingredients (APIs) and special...ty chemicals across the globe. With a strong emphasis on innovation and customer satisfaction, Supriya strives to be a reliable partner to pharmaceutical companies worldwide, offering a diverse portfolio of products targeting a broad spectrum of therapeutic areas. The company leverages advanced manufacturing processes and a dedicated research and development team to ensure product excellence and meet the stringent regulatory requirements of the global pharmaceutical market. Supriya Lifescience is committed to advancing healthcare by providing essential building blocks for life-saving medications. The company’s comprehensive API range covers critical therapeutic segments including treatments for respiratory ailments such as antihistamines and anti-asthmatics, pain management solutions comprising analgesics and anesthetics, cardiovascular health with anti-hypertensives, and essential vitamins. Supriya also provides APIs for oncology, veterinary medicine, and general healthcare, demonstrating its wide-ranging capabilities and commitment to addressing diverse medical needs. Furthermore, the company continues to expand its product line through strategic collaborations and in-house research, solidifying its position as a versatile and adaptive player in the pharmaceutical landscape. Beyond APIs, Supriya Lifescience demonstrates its commitment to innovative healthcare solutions through the development of specialized products like GelHeal, an advanced wound care solution. This showcases the company’s dedication to addressing specific patient needs with cutting-edge technology. Driven by a customer-centric approach and a commitment to ethical practices, Supriya Lifescience Ltd aims to consistently deliver high-quality products, reliable service, and sustainable growth, contributing significantly to the advancement of global healthcare.
Company Details
Key Leadership
Corporate Events
Latest News
SUPRIYA Share Price: Frequently Asked Questions
What is the current share price of Supriya Lifescience Ltd (SUPRIYA)?
As of 30 Mar 2026, 12:04 pm IST, Supriya Lifescience Ltd share price is ₹561.90. The SUPRIYA stock has a market capitalisation of ₹6.00K (Cr) on NSE/BSE.
Is SUPRIYA share price Overvalued or Undervalued?
SUPRIYA share price is currently trading at a P/E ratio of 32.91x, compared to the industry average of 31.77x. Based on this relative valuation, the Supriya Lifescience Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of SUPRIYA share price?
The 52-week high of SUPRIYA share price is ₹842.00 and the 52-week low is ₹545.50. These values are updated daily from NSE/BSE price data.
What factors affect the Supriya Lifescience Ltd share price?
Key factors influencing SUPRIYA share price include quarterly earnings growth (Sales Growth: 20.31%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Supriya Lifescience Ltd a good stock for long-term investment?
Supriya Lifescience Ltd shows a 5-year Profit Growth of 20.71% and an ROE of 20.75%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in SUPRIYA shares.
How does Supriya Lifescience Ltd compare with its industry peers?
Supriya Lifescience Ltd competes with major peers in the Pharmaceuticals. Investors should compare SUPRIYA share price P/E of 32.91x and ROE of 20.75% against the industry averages to determine competitive standing.
What is the P/E ratio of SUPRIYA and what does it mean?
SUPRIYA share price has a P/E ratio of 32.91x compared to the industry average of 31.77x. Investors pay ₹33 for every ₹1 of annual earnings.
How is SUPRIYA performing according to Bull Run's analysis?
SUPRIYA has a Bull Run fundamental score of 62.2/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SUPRIYA belong to?
SUPRIYA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Supriya Lifescience Ltd share price.
What is Return on Equity (ROE) and why is it important for SUPRIYA?
SUPRIYA has an ROE of 20.75%, which indicates excellent management efficiency. ROE measures how efficiently Supriya Lifescience Ltd generates profits from shareholders capital.
How is SUPRIYA debt-to-equity ratio and what does it indicate?
SUPRIYA has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is SUPRIYA dividend yield and is it a good dividend stock?
SUPRIYA offers a dividend yield of 0.13%, meaning you receive ₹0.13 annual dividend for every ₹100 invested in Supriya Lifescience Ltd shares.
How has SUPRIYA share price grown over the past 5 years?
SUPRIYA has achieved 5-year growth rates of: Sales Growth 17.45%, Profit Growth 20.71%, and EPS Growth -14.16%.
What is the promoter holding in SUPRIYA and why does it matter?
Promoters hold 68.30% of SUPRIYA shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Supriya Lifescience Ltd.
What is SUPRIYA market capitalisation category?
SUPRIYA has a market capitalisation of ₹6001 crores, placing it in the Mid-cap category.
How volatile is SUPRIYA stock?
SUPRIYA has a beta of N/A. A beta > 1 suggests the Supriya Lifescience Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SUPRIYA operating profit margin trend?
SUPRIYA has a 5-year average Operating Profit Margin (OPM) of 35.97%, indicating the company's operational efficiency.
How is SUPRIYA quarterly performance?
Recent quarterly performance shows Supriya Lifescience Ltd YoY Sales Growth of 20.31% and YoY Profit Growth of 9.27%.
What is the institutional holding pattern in SUPRIYA?
SUPRIYA has FII holding of 5.46% and DII holding of 5.22%. Significant institutional holding often suggests professional confidence in the Supriya Lifescience Ltd stock.